Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression

11 May 2021

Abstract excerpt

Hormone-receptor positive (HR+) breast cancer (BC) (including the luminal A and the luminal B subtypes) is the most common type of tumor in women diagnosed with early-stage BC (EBC). It represents a highly heterogeneous subgroup that is characterized by different risks of relapse. The aim of this review is to discuss the possible role played by the immune response in predicting this risk, along with the most...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer Immunotherapy and Biomarkers
Share to Chronic Lymphocytic Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33974235
DOI: 10.1007/s40291-021-00525-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune SuppressionPMID 33974235Read ↗

Breast cancer genomics and immuno-oncological markers to guide immune therapiesSemantic proximity Read ↗

Immune Landscape of Breast CancersSemantic proximity Read ↗

Characteristics of the clinicopathology and immune microenvironment of the basal-like phenotype in HR+/HER2-breast cancerSemantic proximity Read ↗

Classification of triple-negative breast cancer based on immune cell infiltrationSemantic proximity Read ↗

Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature ReviewSemantic proximity Read ↗

The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer BiomarkersSemantic proximity Read ↗

Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling.Semantic proximity Read ↗

Immune and gene-expression profiling in estrogen receptor low and negative early breast cancerSemantic proximity Read ↗

The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer SubtypesSemantic proximity Read ↗

Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives.Semantic proximity Read ↗

Antigen-Presenting B-Cell Signature Predicts Response and Survival in HER2-Positive Breast CancerSemantic proximity Read ↗

Determination of HLA-DR level in cytotoxic T lymphocytes: a new validated tool to predict breast cancer response to treatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.